265 filings
Page 4 of 14
SC 13G/A
GLMD
Galmed Pharmaceuticals Ltd
14 Feb 22
Galmed Pharmaceuticals / Nantahala Capital Management ownership change
8:14am
SC 13G/A
Baharaff Allen
11 Feb 22
Galmed Pharmaceuticals / Baharaff Allen ownership change
4:30pm
SC 13G/A
Ibex Investors LLC
27 Jan 22
Galmed Pharmaceuticals / Ibex Investors ownership change
4:32pm
6-K
GLMD
Galmed Pharmaceuticals Ltd
11 Jan 22
Galmed Continues to Drive Innovation with Three New US Patents Granted for Aramchol and its Meglumine Salt
8:15am
6-K
GLMD
Galmed Pharmaceuticals Ltd
10 Jan 22
Galmed announces positive results of Phase 1 study of Amilo-5MER
8:11am
6-K
GLMD
Galmed Pharmaceuticals Ltd
8 Nov 21
Galmed Pharmaceuticals Provides Additional Positive Data from the Open Label Part of ARMOR Study and Reports Third Quarter 2021 Financial Results
8:25am
6-K
GLMD
Galmed Pharmaceuticals Ltd
1 Nov 21
Galmed Announces Positive Results from First 16 Patients in Open-Label Part of ARMOR Study
10:23am
6-K
GLMD
Galmed Pharmaceuticals Ltd
12 Oct 21
Results of Galmed’s Phase 2b ARREST Trial of Aramchol Published in Nature Medicine
7:00am
6-K
GLMD
Galmed Pharmaceuticals Ltd
31 Aug 21
Current report (foreign)
4:30pm
6-K
GLMD
Galmed Pharmaceuticals Ltd
23 Aug 21
Current report (foreign)
4:30pm
6-K
GLMD
Galmed Pharmaceuticals Ltd
19 Aug 21
Galmed Pharmaceuticals Announces Publication in “The Journal of Autoimmunity” for its IND ready, Amilo-5MER, a specific anti-inflammatory compound
8:11am
6-K
GLMD
Galmed Pharmaceuticals Ltd
16 Aug 21
MHRA Agrees with Galmed’s Plan to use Aramchol meglumine in the Randomized Double-blind Placebo-Controlled Part of the Phase 3 ARMOR study
8:31am
6-K
GLMD
Galmed Pharmaceuticals Ltd
5 Aug 21
Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2021 Financial Results
7:00am
6-K
GLMD
Galmed Pharmaceuticals Ltd
2 Aug 21
FDA Agrees with Galmed’s Plan to use Aramchol Meglumine in the Randomized Double-Blind Placebo-Controlled Part of the Phase 3 ARMOR study
7:47am
6-K
GLMD
Galmed Pharmaceuticals Ltd
19 Jul 21
Current report (foreign)
4:30pm
6-K
GLMD
Galmed Pharmaceuticals Ltd
2 Jul 21
Current report (foreign)
4:30pm
6-K
GLMD
Galmed Pharmaceuticals Ltd
13 May 21
Galmed Pharmaceuticals Provides Business Updates and Reports First Quarter 2021 Financial Results
8:13am
6-K
GLMD
Galmed Pharmaceuticals Ltd
3 May 21
China to Join Galmed's Phase 3 ARMOR Registrational Study for the Treatment of NASH & Fibrosis
8:42am
EFFECT
GLMD
Galmed Pharmaceuticals Ltd
2 Apr 21
Notice of effectiveness
12:15am
CORRESP
GLMD
Galmed Pharmaceuticals Ltd
1 Apr 21
Correspondence with SEC
12:00am